Advances and prospects of drug clinical research in colorectal cancer in 2022.
Dan SuChao LiuJie CuiJiebing TangYuli RuanYan-Qiao ZhangPublished in: Cancer innovation (2023)
Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer death worldwide. Clinical research results have provided more treatment opportunities for CRC patients, showing that an optimal combination of existing drugs and new drugs is needed to mitigate the burden of this disease. In this review, we have summarized recent advances in drug clinical research for CRC in 2022, including chemotherapy, targeted therapy, and immunotherapy, to find opportunities for substantial improvements in drug discovery and clinical development methods.
Keyphrases
- drug discovery
- papillary thyroid
- end stage renal disease
- squamous cell
- ejection fraction
- newly diagnosed
- drug induced
- chronic kidney disease
- peritoneal dialysis
- squamous cell carcinoma
- emergency department
- lymph node metastasis
- adverse drug
- patient reported outcomes
- locally advanced
- young adults
- patient reported
- electronic health record